Switching to riociguat: a potential treatment strategy for the management of CTEPH and PAH

Switching to riociguat: a potential treatment strategy for the management of CTEPH and PAH

Currently, five classes of drug are approved for the treatment of pulmonary arterial hypertension (PAH): phosphodiesterase 5 inhibitors (PDE5i); endothelin receptor antagonists; prostacyclin analogs; the IP receptor agonist selexipag; and the soluble guanylate cyclase (sGC) stimulator riociguat. For...

Full description

Bibliographic Details
Main Authors: Raymond L. Benza, Paul A. Corris, Hossein-Ardeschir Ghofrani, Manreet Kanwar, Vallerie V. McLaughlin, Amresh Raina, Gérald Simonneau
Format: Article
Language:English
Published: Wiley 2020-03-01
Series:Pulmonary Circulation
Online Access:https://doi.org/10.1177/2045894019837849

Similar Items

Similar Items